Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
TQJ230 - Antisense oligonucleotide targeting
apolipoprotein(a) mRNA
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04023552 Lp(a) HORIZON (CTQJ230A12301)
Cardiovascular risk reduction
Phase 3
7680
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal
stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically
significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL
Target Patients
Read-out Milesstone(s)
2024
Publication
TBD
69 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation